Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 35; H. 10; S. 1112
Hauptverfasser:	Moore, Kathleen N, Martin, Lainie P, O'Malley, David M, Matulonis, Ursula A, Konner, Jason A, Perez, Raymond P, Bauer, Todd M, Ruiz-Soto, Rodrigo, Birrer, Michael J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.04.2017
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Diarrhea - chemically induced Disease-Free Survival Drug Resistance, Neoplasm Fallopian Tube Neoplasms - chemistry Fallopian Tube Neoplasms - drug therapy Fatigue - chemically induced Female Folate Receptor 1 - analysis Folate Receptor 1 - antagonists & inhibitors Humans Hypotension - chemically induced Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Maytansine - adverse effects Maytansine - analogs & derivatives Maytansine - therapeutic use Middle Aged Nausea - chemically induced Ovarian Neoplasms - chemistry Ovarian Neoplasms - drug therapy Peritoneal Neoplasms - chemistry Peritoneal Neoplasms - drug therapy Platinum Compounds - therapeutic use Response Evaluation Criteria in Solid Tumors Retreatment Vision Disorders - chemically induced
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!